PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy-Reference-Cited by-同舟云学术

PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy

Published:2019-02-19 Issue:10 Volume:234 Page:16824-16837
ISSN:0021-9541
Container-title:Journal of Cellular Physiology
language:en
Short-container-title:J Cell Physiol

Author:

Salmaninejad Arash¹²^ORCID,Valilou Saeed Farajzadeh³,Shabgah Arezoo Gowhari⁴,Aslani Saeed⁵,Alimardani Malihe²,Pasdar Alireza²⁶,Sahebkar Amirhossein⁷⁸⁹

Affiliation:

1. Drug Applied Research Center Tabriz University of Medical Sciences Tabriz Iran

2. Student Research Committee, Department of Medical Genetics, Medical Genetics Research Center Faculty of Medicine, Mashhad University of Medical Sciences Mashhad Iran

3. Medical Genetics Network (MeGeNe) Universal Scientific Education and Research Network (USERN) Tehran Iran

4. Department of Immunology Mashhad University of Medical Sciences Mashhad Iran

5. Rheumatology Research Center Tehran University of Medical Sciences Tehran Iran

6. Division of Applied Medicine Medical School, University of Aberdeen Aberdeen UK

7. Biotechnology Research Center Pharmaceutical Technology Institute, Mashhad University of Medical Sciences Mashhad Iran

8. Neurogenic Inflammation Research Center Mashhad University of Medical Sciences Mashhad Iran

9. School of Pharmacy, Mashhad University of Medical Sciences Mashhad Iran

Publisher

Wiley

Subject

Cell Biology,Clinical Biochemistry,Physiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcp.28358

Reference128 articles.

1. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer

2. Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

3. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

4. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032.

5. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

Cited by 302 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Review of immunotherapy in non-small cell lung cancer: mechanisms, clinical applications, and future prospects;Asia-Pacific Journal of Oncology;2024-09-11

3. Targeting autophagy can synergize the efficacy of immune checkpoint inhibitors against therapeutic resistance: New promising strategy to reinvigorate cancer therapy;Heliyon;2024-09

4. Hydrophilic biomaterials: From crosslinked and self-assembled hydrogels to polymer-drug conjugates and drug-free macromolecular therapeutics;Journal of Controlled Release;2024-09

5. Surface Immune Checkpoints as Potential Biomarkers in Physiological Pregnancy and Recurrent Pregnancy Loss;International Journal of Molecular Sciences;2024-08-29